WINTON GROUP Ltd Acquires New Stake in IQVIA Holdings Inc. $IQV

WINTON GROUP Ltd bought a new position in shares of IQVIA Holdings Inc. (NYSE:IQV) in the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund bought 26,115 shares of the medical research company’s stock, valued at approximately $5,046,000.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Financial Freedom LLC bought a new stake in shares of IQVIA during the 1st quarter valued at about $25,000. Ascentis Independent Advisors bought a new position in shares of IQVIA in the first quarter worth approximately $25,000. International Assets Investment Management LLC purchased a new stake in IQVIA in the fourth quarter valued at approximately $27,000. Compass Financial Management LLC purchased a new stake in IQVIA in the second quarter valued at approximately $27,000. Finally, Gilpin Wealth Management LLC bought a new stake in IQVIA during the fourth quarter valued at approximately $27,000. Hedge funds and other institutional investors own 89.62% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on IQV shares. JPMorgan Chase & Co. increased their price target on shares of IQVIA from $225.00 to $285.00 and gave the stock an “overweight” rating in a report on Wednesday, July 29th. Stifel Nicolaus lifted their price objective on shares of IQVIA from $220.00 to $276.00 and gave the stock a “buy” rating in a report on Wednesday, July 29th. Mizuho upped their target price on shares of IQVIA from $215.00 to $230.00 and gave the stock an “outperform” rating in a research report on Monday, July 13th. Wall Street Zen cut IQVIA from a “buy” rating to a “hold” rating in a research note on Saturday, August 29th. Finally, BMO Capital Markets raised their price target on IQVIA from $210.00 to $270.00 and gave the company an “outperform” rating in a research report on Wednesday, July 29th. One analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and three have given a Hold rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $243.62.

Insider Buying and Selling

In related news, insider Eric Sherbet sold 5,000 shares of the company’s stock in a transaction on Wednesday, July 29th. The shares were sold at an average price of $249.16, for a total transaction of $1,245,800.00. Following the completion of the sale, the insider directly owned 20,999 shares in the company, valued at $5,232,110.84. This represents a 19.23% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, insider Bhavik Patel sold 1,855 shares of the firm’s stock in a transaction on Friday, July 31st. The stock was sold at an average price of $235.27, for a total transaction of $436,425.85. Following the completion of the sale, the insider directly owned 1,348 shares in the company, valued at approximately $317,143.96. This trade represents a 57.91% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 15,581 shares of company stock valued at $3,796,021 over the last quarter. Company insiders own 1.70% of the company’s stock.

IQVIA Stock Up 0.2%

Shares of NYSE:IQV opened at $257.54 on Friday. The stock has a market capitalization of $42.39 billion, a P/E ratio of 31.95, a price-to-earnings-growth ratio of 2.19 and a beta of 1.18. The stock’s 50-day moving average price is $235.44 and its 200-day moving average price is $195.46. The company has a current ratio of 0.71, a quick ratio of 0.71 and a debt-to-equity ratio of 2.18. IQVIA Holdings Inc. has a 12-month low of $154.50 and a 12-month high of $271.80.

IQVIA (NYSE:IQV) last issued its earnings results on Tuesday, July 28th. The medical research company reported $3.15 earnings per share for the quarter, beating the consensus estimate of $3.03 by $0.12. The company had revenue of $4.37 billion during the quarter, compared to analysts’ expectations of $4.30 billion. IQVIA had a return on equity of 30.25% and a net margin of 8.10%.IQVIA’s quarterly revenue was up 8.7% compared to the same quarter last year. During the same period in the prior year, the business posted $2.81 EPS. IQVIA has set its FY 2026 guidance at 12.800-13.000 EPS. On average, equities analysts anticipate that IQVIA Holdings Inc. will post 11.57 earnings per share for the current year.

About IQVIA

IQVIA Holdings Inc is a global provider of advanced analytics, technology solutions and contract research services for the life sciences industry. The company supports pharmaceutical, biotechnology and medical device companies throughout the product life cycle, from research and clinical development through commercialization and post-market activities.

Its offerings include clinical trial management, site and patient services, real-world evidence, healthcare data, regulatory and safety services, commercial analytics, consulting, and technology platforms.